The history of human self-modification is already long. We educate children, discipline attention, reward conformity, punish aggression, teach emotional regulation, encourage ambition, prescribe medication, celebrate alcohol, regulate other drugs, design workplaces, build rituals, structure sleep, and surround people with technologies engineered to hold or redirect attention.
Personality has never been socially untouched.
What may change is the precision with which intervention becomes possible.
If personality pharmacology matures, society will gain better tools for estimating psychological state, predicting response to perturbation, and selectively changing dimensions such as attention, confidence, threat sensitivity, emotional intensity, wakefulness, social affiliation, or cognitive flexibility.
That possibility is exciting for the same reason it is dangerous: personality determines what people want as well as how effectively they pursue it.
The obvious opportunity is medicine. A psychiatry that understands baseline heterogeneity could reduce years of ineffective treatment. Instead of cycling through drugs based largely on diagnosis and population averages, clinicians might identify dimensions that predict response. Treatment could target restoration of agency, functional range, and context fit rather than simply lowering symptom totals.
The second opportunity is education. Students differ in arousal, novelty seeking, attention, social sensitivity, reward, and tolerance for structure. Modern schooling often treats those differences as noise around one preferred learning style. A state-based model could instead ask which environments help a student enter productive modes and when temporary biological or behavioral support is justified.
Work could change similarly. Some tasks require exploration, others verification. Some people perform best with long uninterrupted blocks; others with novelty and social exchange. Instead of selecting one ideal worker, organizations could design for a portfolio of temperaments and cognitive modes.
Left Week and Right Week scale from the individual to the institution.
A research team could explicitly separate generative phases from adversarial review. A company could protect exploratory work from premature quarterly optimization. A hospital could value both cautious sentinels and decisive actors. Temperament diversity could become an asset to design around rather than a deviation to correct.
Then comes the darker version.
Employers may prefer workers who need less sleep, tolerate monotony, remain emotionally stable under unreasonable demands, and sustain focus indefinitely. Schools may prefer compliant attention. Militaries may value reduced fear. Prisons may value docility. Partners may prefer greater attachment. Governments may prefer trust or conformity.
A technology for increasing agency in the hands of the individual can become a technology for increasing governability in the hands of an institution.
The danger is not personality modification itself. Humans already modify one another constantly. The danger is asymmetry of power over the direction of modification.
This makes coercion broader than forced medication. If refusing an enhancement makes employment impossible, the choice may be formally voluntary and practically compulsory. If everyone in a profession uses a concentration-enhancing intervention, the untreated baseline becomes a competitive disadvantage. If insurance pays for medication that helps a person tolerate a harmful environment but not for changing the environment, economic architecture chooses the personality target indirectly.
The politics of personality will therefore be partly the politics of defaults.
Which traits receive medical labels? Which interventions are subsidized? Which are prohibited? Which personality styles are rewarded by schools and employers? Which are treated as pathology? Who owns the data used to infer psychological state? Can an insurer or employer demand access to predicted impulsivity, addiction vulnerability, emotional stability, or treatment response?
Privacy becomes identity privacy.
Fairness becomes complicated as well. If some people can safely increase focus, confidence, or cognitive endurance, unequal access may amplify existing inequality. Yet forbidding enhancement can also preserve arbitrary biological luck. The ethical aim cannot simply be equal outcomes or equal natural baselines.
A stronger principle is fair opportunity combined with freedom of refusal.
People should not be excluded from valuable, reasonably safe tools solely because personality modification makes others uncomfortable. Nor should they be forced to use those tools to remain economically viable.
The right to remain unoptimized is part of the right to self-authorship.
Culture will push in both directions. Some subcultures will romanticize the natural self. Others will treat continual optimization as moral duty. Both positions can become coercive. Naturalness can shame people who benefit from medication. Optimization culture can shame people who value rest, emotional intensity, eccentricity, or ordinary limitation.
Personality pharmacology should reject both orthodoxies.
The book began with the mutable self. It ends with the question of who should govern that mutability.
Homo Integralis provides one possible answer, but only if the archetype is understood correctly. The integrated person is not chemically perfected. They are not maximally productive, permanently calm, universally sociable, or endlessly open. They possess something closer to psychological jurisdiction: a broad but controlled repertoire, awareness of their own modes, and the capacity to move among them without surrendering reality contact or reflective choice.
The ideal scales socially as well. A neurochemical society worthy of the name would not manufacture one preferred temperament. It would preserve diversity while giving people better tools to understand and, when they choose, alter their own starting conditions.
That society would treat the population mean as a statistic, not a command.
It would distinguish suffering from rarity. It would ask whether a workplace should change before asking whether the worker should. It would recognize that drugs can increase or decrease agency depending on baseline. It would measure long-term endorsement rather than assuming every acute preference is authoritative. It would protect children and vulnerable people from premature or coercive modification. It would permit competent adults meaningful latitude over their own minds while preserving limits where risks fall heavily on others.
Most importantly, it would remain uncertain.
The science of personality pharmacology may discover that some hoped-for forms of modification are unreliable or unsafe. The neurotransmitter maps in this book may be substantially revised. Some dimensions may prove less biologically stable than expected. Precision models may add only modest predictive power. The ethical problems may become harder as the technology improves.
None of that would erase the foundational observation.
The psychological baseline is a contingent biological and developmental state. It can be moved. Human beings already spend much of life trying to move it.
The responsible project is therefore not to defend the baseline as sacred or to celebrate every departure from it. It is to understand the control architecture well enough that movement becomes more deliberate, measurable, reversible, and answerable to the person whose mind is being changed.
The goal is not one better human type.
It is less unnecessary suffering, better context fit, wider functional range, stronger reality contact, and greater authorship over the states from which a person meets the world.
The human baseline is a starting condition.
What follows from it should increasingly be ours to understand.